Share Name Share Symbol Market Type Share ISIN Share Description
Arix Bioscience Plc LSE:ARIX London Ordinary Share GB00BD045071 ORD 0.001P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -3.50 -2.89% 117.50 115.00 120.00 121.00 117.50 121.00 18,500 08:31:14
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 1.3 42.8 32.1 3.7 159

Arix Bioscience Share Discussion Threads

Showing 101 to 124 of 125 messages
Chat Pages: 5  4  3  2  1
DateSubjectAuthorDiscuss
06/11/2019
12:09
Autolus shares are starting to recover so hopefully we will also see a pop in the NAV.
the shuffle man
06/11/2019
11:52
News reports suggesting Woodford stake in Arix close to being sold to a hedge fund as part of a bundle of his illiquid life sciences holdings . Expect a sharp pop as soon as overhang officially cleared
nchanning
23/10/2019
13:38
Does ARIX have the means, or authority, to buy back its shares from Woodford/Blackrock? If they believe the company is significantly undervalued at this share price, it might make some sense to do so.
hashertu
20/10/2019
14:40
#HVO Equity Income Fund was suspended in June. Companies such as #Tissue #Regenix, #Synairgen, #Arix ... https://thismon.ee/a/7591003 via @ThisIsMoney
newtothisgame3
17/10/2019
17:53
Re WIM. ARIX is a cert for the non liquid pot! What happens next? FCA rules mean investors must be given three months’ notice before a fund can be wound up. So the process of liquidating the fund will begin on 17 January 2020. In the meantime, Link has divided the Equity Income Fund into two parts. The first contains listed assets that can easily be traded. These will be taken over by US investment giant Blackrock. Blackrock will sell these shares and switch the money into money market funds and FTSE 100 index securities, ahead of liquidation. The remainder of the Equity Income Fund consists of unlisted and hard-to-sell listed assets. These are being handled by a specialist adviser (Park Hill - httPs://pjtpartners.com/pjtparkhill ) who will work to find buyers for these assets. After 17 January, Blackrock will liquidate its part of the portfolio. The cash will be returned to shareholders — Link says it hopes to make the first payment by the end of January. Further payments will be made when possible, after the deduction of fees incurred in the liquidation of the fund. If you’re an investor in the Woodford Equity Income Fund, you should receive a letter from Link Fund Solutions with more details. The liquidation will apply to all investors in the fund.
rambutan2
17/10/2019
12:53
Looks like a certain "Link Fund Solutions" has took out Woodford entire remaining holding.
dave4545
15/10/2019
20:20
Cheers Ram should have looked a bit closer. Hopefully Blackrock will shift them quickly.
the shuffle man
15/10/2019
19:47
The rns is not for a sale but due to fact that WIM sacked/resigned as manager. The stake remains in the fund/s, unfortunately.
rambutan2
15/10/2019
15:11
Hopefully this will recover now, discount is too large.
the shuffle man
15/10/2019
14:34
Looks like a placement has been completed as Woodford stake is now less than 5%. Just bought a few more.
stevenb3
15/10/2019
08:44
Looks like the Woodford Fund is being wound up and cash will be returned to investors. Hopefully they already have a buyer lined up for their stake here otherwise a big overhang. I assume this is why the price has been so weak recently and surely represents a buying opportunity.
the shuffle man
13/9/2019
15:23
Autolus continues to recover. I estimate NAV currently around £1.73, so the current share price is at a discount of around 30% of NAV.
tim000
10/9/2019
07:30
Autolus rose further yesterday, if a more muted increase than the previous two days. Looking through the portfolio, there is lots of important news in the pipeline, including various Phase 3 trials reporting over the next 3-6 months. ARIX reports 28 clinical trials are in progress across the portfolio.
tim000
09/9/2019
13:00
That would certainly help, but I don’t think it essential. I think the ARIX team are pretty good scientists and hopefully have invested wisely. So there should be plenty of upside over the medium term from companies like Autolus, irrespective of what Woodford does. Indeed, if you go through the portfolio company by company, the listed ones to date have generally shown good capital appreciation so far.
tim000
09/9/2019
12:49
Thanks so Woodford just needs to offload his stake in Arix now and we should fly !
the shuffle man
09/9/2019
09:13
Shuffle Man, see link below: hxxps://www.proactiveinvestors.co.uk/companies/news/902235/arix-jumps-as-woodford-finally-sells-stake-in-autolus-therapeutics-902235.html
tim000
09/9/2019
08:52
Thanks Tim I took a holding on Friday. Do you think Woodford has sold a lot more of his holding here. The last RNS from 8th July still shows he has 19%.
the shuffle man
09/9/2019
08:21
I've been a buyer today. I agree, they look incredibly cheap. If one strips out their uncommitted cash, the shares are currently trading at a discount of over 40 % to NAV of the portfolio. The true discount is a lot larger, since Autolus (which currently accounts for 17% of total NAV) has been hammered by factors unrelated to its underlying value - namely Woodford, who has now sold much of his holding. You've probably noticed that Autolus has risen about 40% in the past two days, I expect that to continue as it's currently trading at a 40% discount to its latest capital raise. Were the Autolus share price to return to that level, ARIX's NAV would increase by 20p per share. Finally, over half of ARIX's portfolio is located in the US and is valued in $. So future sterling weakness against the $ (which seems likely) will further increase ARIX's NAV.
tim000
06/9/2019
09:45
Been following for a while. They look cheap with a big discount to NAV and problems at Autolus seem to be getting better with the shares up 20% last night. Any views please.
the shuffle man
14/8/2019
14:02
Woodford dump underway? Short attack?
typo56
08/6/2019
19:38
Yes x2 ie WIM’s large direct stake in ARIX, and also the plummet in AUTL’s share price due to WIM’s large stake in that, which is of course ARIX’s largest holding. And on top of that, who read the AGM voting rns? The greedy management are hopefully going to start pruning their pay! https://uk.advfn.com/stock-market/london/arix-bioscience-ARIX/share-news/Arix-Bioscience-plc-Correction-Result-of-AGM/80056948
rambutan2
04/6/2019
09:28
Looks like the Woodford issues are having an effect here?
chesil356
04/4/2019
06:34
Rambutan.Do you not agree that the AUTO1 results were excellent?I have posted on Advfn Syncona thread and also Lse but with no response.It really beggars belief!!
ltinvestor
03/4/2019
02:53
Funding and uplift: LONDON, 2 April 2019: Arix Bioscience plc (“Arix”, LSE: ARIX) a global venture capital company focused on investing and building breakthrough biotech companies, today announces that it has committed $4.5 million (£3.4 million1) to the $40 million (£31 million) Series D financing (“the financing”) of Aura Biosciences htTp://www.aurabiosciences.com , a leader in the development of novel targeted therapies in ocular oncology. Following this commitment, Arix increases its stake to 7.7% on a fully diluted basis. Arix Investment Director Mark Chin will continue to serve on the Aura Board. The financing recognised a 33% uplift in the book value of Arix’s Series C investment in Aura, with Arix’s total interest in Aura increasing to £8.5 million from £3.9 million on a fully committed basis. htTps://polaris.brighterir.com/public/arix_bioscience/news/rns/story/xov7l1r
rambutan2
Chat Pages: 5  4  3  2  1
Your Recent History
LSE
ARIX
Arix Biosc..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191111 22:12:51